Chrysanthemol (1), a trans-eudesmane type sesquiterpene from Chrysanthemum indicum L., possesses certain anti-inflammatory activity. Its total synthesis was approached from two alternative routes and finally accomplished in ten steps from R-(+)-carvone via alpha-eudesmol (10) as the key intermediate. The overall yield is 2.4% and the spectral data of the synthetic target compound were identical with that of natural chrysanthemol (1). Seven intermediary compounds were tested for inhibitory effects on the carragenan-induced swelling of mouse paw but demonstrated no obvious activities.
